肝脏X受体激动剂T0901317可逆转A549人肺癌细胞对EGFR-TKI治疗的耐药性。
Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR-TKI treatment.
作者信息
Cao Haixia, Yu Shaorong, Chen Dan, Jing Changwen, Wang Zhuo, Ma Rong, Liu Siwen, Ni Jie, Feng Jifeng, Wu Jianzhong
机构信息
Research Center for Clinical Oncology Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research Nanjing Medical University Affiliated Cancer Hospital Jiangsu Province China.
Research Center for Clinical Oncology Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research Nanjing Medical University Affiliated Cancer Hospital Jiangsu Province China; Department of Oncology Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research Nanjing Medical University Affiliated Cancer Hospital Jiangsu Province China.
出版信息
FEBS Open Bio. 2016 Dec 20;7(1):35-43. doi: 10.1002/2211-5463.12147. eCollection 2017 Jan.
Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is effective in lung cancer patients carrying sensitive EGFR mutations. In this study, we investigated if liver X receptor (LXR) agonist T0901317 could reverse the resistance of lung cancer cell lines A549 and H1650 to EGFR-TKI treatment. We found that T0901317 could make natural EGFR-TKI-resistant A549 human lung cancer cells sensitive to EGFR-TKI treatment and that this was dependent on LXRβ expression. However, T0901317 does not have a similar effect on another natural EGFR-TKI-resistant cell line H1650.
表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）对携带敏感EGFR突变的肺癌患者有效。在本研究中，我们调查了肝脏X受体（LXR）激动剂T0901317是否能逆转肺癌细胞系A549和H1650对EGFR-TKI治疗的耐药性。我们发现T0901317可使天然EGFR-TKI耐药的A549人肺癌细胞对EGFR-TKI治疗敏感，且这依赖于LXRβ的表达。然而，T0901317对另一种天然EGFR-TKI耐药细胞系H1650没有类似作用。
Zotero 插件